BianoGMP GmbH receives investment capital from the Thuringia Start-up Fund (TSF) for the production of DNA- and RNA-based active agents.
There is still a lack of sufficiently effective therapies for a number of serious diseases. However, a large number of small companies and research groups at universities are already working on new, better active substances for such diseases. In recent years, the focus has often been on molecular biology, DNA- and RNA-based active substances, but also on the recently developed “gene scissors”. However, before these innovative active substances can be clinically tested in patient studies, they have to be produced in pharmaceutical quality (GMP = “Good Manufacturing Practice”). “BianoGMP GmbH will establish itself as a partner and service provider for the developers of these new, highly potent active substances and pave the way for them to enter the clinic by manufacturing them in pharmaceutical quality,” Stefan Jahn, Investment Manager at bm‑t beteiligungsmanagement thüringen gmbh (bm|t), is convinced.
The BianoGMP team has been working on RNA agents for a long time and developed a new class of patented RNA agents as part of a funded project with Friedrich Schiller University in Jena. “Our partner company BianoScience GmbH will be among the first clients for whom we produce active substances for clinical trials. However, patients will also benefit from our service by gaining accelerated access to new, innovative therapies” says Dr Tobias Pöhlmann, Managing Director of BianoGMP.
Dr. Rolf Günther, second managing director of BianoGMP, emphasises the role of the region: “The investment of bm|t, Mittelständische Beteiligungsgesellschaft Thüringen mbH and several private investors, the majority of whom are based in Eastern Thuringia, allows us to establish a technically sophisticated and efficient production facility at the Gera airfield. In this way, we can offer the drug developers to bring their novel developments to the clinic together with us more efficiently and faster than before.”
The bm‑t beteiligungsmanagement thüringen gmbh, based in Erfurt, is a subsidiary of the Thüringer Aufbaubank and the first address for investments in Thuringia. bm|t currently manages eight funds with a total invested volume of around €320 million, which invest in innovative companies in almost all sectors and in all phases of company development — both in the start-up and growth phases or in company succession situations.
Mittelständische Beteiligungsgesellschaft Thüringen mbH has been established in Thuringia for 25 years. With well over 100 investments in its portfolio, it successfully implements economic development for start-ups, existing companies and successions.
The company is a start-up in Gera and is based on foundations laid in a project of the biotechnology start-up offensive at Friedrich Schiller University Jena, funded by the Federal Ministry of Education and Research. BianoGMP produces DNA- and RNA-based active substances under GMP on behalf of drug developers.
bm‑t participation management thüringen gmbh
Stefan Jahn and Katrin Uschmann
Phone: +49 361 7447 601
Fax: +49 361 7447 635